METHOD FOR PREVENTING THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C AND RECEIVING COMBINATION ANTIVIRAL THERAPY Russian patent published in 2015 - IPC A61K35/14 A61P7/00 

FIELD: medicine.

SUBSTANCE: invention can be used to prevent thrombocytopenia developing in the patients with chronic hepatitis C (CHC) as a result of a combination antiviral therapy (CAT). That is ensured by daily intravenous administrations of autoblood haemolysate (ABH) exactly 10 days before the beginning of the CAT in the CHC patients in need of the CAT; from the beginning and throughout the duration of the CAT course, the ABH intravenous administration continues in the same dose, however every 7 days; the ABH intravenous administration is combined with taking patient's blood 10.0 ml in a syringe 20.0 ml 50% pre-filled with distilled water; thereafter, with a puncture needle kept inserted, autoblood haemolysate produced in the syringe is re-injected into a vascular bed.

EFFECT: method enables reducing a ratio of patients suffering moderate and severe CAT-associated thrombocytopenia.

1 tbl, 1 ex